Novartis: asthma treatment fails to meet trial endpoint

(CercleFinance.com) - Novartis said on Monday that its investigational, steroid-free once-daily pill fevipiprant, used against uncontrolled asthma, failed to meet the primary endpoint of two late-stage trials.


The trials did not meet the clinically relevant threshold for reduction in rate of moderate -to-severe exacerbation compared to placebo over a 52-week treatment period for either of the doses.

These "disappointing" results do not support further development of fevipiprant in asthma, Novartis said.

Copyright (c) 2019 CercleFinance.com. All rights reserved.